There are no events in the calendar at the moment
The history of Zenicor
Zenicor Medical Systems AB was formed in 2003 in Stockholm and has since the start been focused on early, easy and effective diagnosis of arrhythmias.
Together with researchers from Karolinska Institutet, an initial system was developed for easy ECG registration outside the hospital, connected to a web-based service for ECG interpretation. This system was introduced to the market in 2004. The product immediately attracted attention among Swedish cardiologists, which lead to a number of rapid orders from reputable hospitals. With lessons learned from this initial product and feedback from the market, in 2010 Zenicor was able to launch a proprietary device with improved functionality and automatic ECG data transfer via the mobile network. At the same time the new web-based service (The Doctor system) was launched with a large number of new functions to simplify the diagnostic work of care providers and make it more effective.
The partnership with Karolinska Institutet has also involved validating the scientific efficacy of the method and to creating an offering with obvious medical benefit. The partnership with prominent researchers in all markets has been crucial. It has strongly contributed and is still contributing to Zenicor’s success.
Originally, sales were made in the Swedish market through the company’s own sales organisation with great success. In 2007 an export campaign was launched in collaboration with Business Sweden, which assisted with market analysis and initiating sales activities in the export markets.
In 2014 the Zenicor stock was listed on the Swedish MTF (multilateral trading facility) ”Aktietorget/Spotlight Stock Market” and financial resources were raised to be able to build a sales organisation in the export markets. In recent years Zenicor has been successful in its efforts to build up an international sales organisation. Deals with partners and distributors have been made and several successful projects have been carried out together with leading pharmaceutical- and medical technology companies.
During 2016 and 2017 the first early diagnosis projects in Finland, Denmark, Austria, Germany and Great Britain have been started and during the last years several important scientific publications have been made that have been recieved with great international interest and among other things lead to updated European guidelines for the management of atrial fibrillation patients.